Gulam Manji, MD, PhD, and Matthew Ingham, MD, of the Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia/NewYork-Presbyterian, have recently been named Next Gen Innovators by HemOnc Today. In its third year, the honor goes to a select group of early career hematologists and oncologists recognized by the publication for advancing their field through innovative approaches in clinical and research settings.
Dr. Manji is an assistant professor of medicine at Columbia and director of medical oncology and translational research for the Pancreas Center. He conducts translational research with the overall goal of developing new treatments for cancer, and cares for patients with gastrointestinal malignancies, focusing on pancreatic and liver cancers, and sarcomas. His research expertise is in gastrointestinal malignancies, particularly pancreas adenocarcinoma, on which he is conducting preclinical combination immunotherapy studies with collaborators at the HICCC. Dr. Manji received a Young Investigator award from the American Society of Clinical Oncology (ASCO) in 2015 to support his work in identifying novel combination cancer immunotherapies.
Dr. Ingham, assistant professor of medicine at Columbia, specializes in sarcoma and gastrointestinal cancers and is an active member of the experimental therapeutics unit. His research focuses on the development and clinical evaluation of novel targeted and immune-based therapies for the treatment of patients with sarcoma. He is leading a newly opened clinical trial for sarcoma patients, exclusive at Columbia/NewYork-Presbyterian, using immunotherapy, APX005M (an antibody targeting CD40), in combination with standard chemotherapy to stimulate an immune response in sarcoma. He recently received Conquer Cancer Foundation’s prestigious Career Development award.
Drs. Manji and Ingham join HemOnc Today’s new class of 111 leading oncologists and researchers tapped Next Gen Innovators who were honored at a reception at ASCO's annual meeting, held May 31 to June 4, 2019.